Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitorsFeng Zhou, Chengzhi Zhou, Baohui Han et al.|ESMO Open|2023Cited by 31
P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLCC. Zhou, Chengping Hu, G. Chen et al.|Journal of Thoracic Oncology|2021Cited by 7